Vol. 3 No. 2 (2026): April - June
28-42
2026-06-29
Open Access

Inotropic Drugs in Decompensated Chronic Heart Failure

Timur A.Abdullayev
Igor A.Tsoy
https://doi.org/10.70626/cardiouz-2026-3-00085

Received: 2026-02-16

Published: 2026-06-29

PDF (Russian)
Crossmark Crossmark

Abstract

Aim. To provide cardiologists with up-to-date information on inotropic agents used in the treatment of acute decompensated heart failure.
Materials and Methods. A systematic literature review on the selected topic was conducted using Google Scholar and PubMed. The text was edited with the assistance of the artificial intelligence system ChatGPT developed by OpenAI to improve readability, followed by final verification by the authors.
Results. Inotropic drugs include both classical cardiac glycosides, currently experiencing a “renaissance, and well-known inotropic agents such as dobutamine, levosimendan, and milrinone. New pharmacological agents, including vericiguat and omecamtiv mecarbil, are also discussed separately.
Conclusion. Inotropic agents are important medications used in the management of patients with decompensated heart failure.

Keywords

List of references

  1. Savarese G, Lund LH. Global public health burden of heart failure. Cardiac Fail Rev. 2017;3(1):7-11.

  2. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. https://doi.org/10.1093/eurheartj/ehab368

  3. Packer M, McMurray JJ, Massie BM, et al. Angiotensin receptor–neprilysin inhibition compared with enalapril for heart failure. N Engl J Med. 2014;371(993):993-1004. https://doi.org/10.1056/NEJMoa140 9077

  4. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009;53(7):557-573. https://doi.org/10.1016/j.jacc.2008.11.049

  5. Mebazaa A, Laribi S, Cohen-Solal A, et al. Recommendations on pre-hospital and early hospital management of acute heart failure. Eur J Heart Fail. 2015;17(6):544-558. https://doi.org/10.1002/ejhf.270

  6. Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013;309(4):355-363. https://doi.org/ 10.1001/jama.2012.216476

  7. Katz AM. Physiology of the Heart. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.

  8. Withering W. An Account of the Foxglove and Some of Its Medical Uses: With Practical Remarks on Dropsy and Other Diseases. Birmingham, UK: G. Robinson; 1785.

  9. Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004;109(24):2959-2964. https://doi.org/10.1161/01.CIR.0000132482.95686.87

  10. Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 13th ed. New York, NY: McGraw-Hill Education; 2018.

  11. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 guideline for the management of patients with atrial fibrillation. Circulation. 2019;140(2):e125-e151. https://doi.org/10.1161/CIR.0000000000000665

  12. Rathore SS, Wang Y, Rumsfeld JS, et al. Serum digoxin levels and mortality in 5102 patients with heart failure receiving digitalis in the DIG trial. N Engl J Med. 2003;349(12):1313-1321. https://doi.org/10.1056/NEJMoa030421

  13. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525-533. https://doi.org/10.1056/NEJM199702203360801

  14. Bavendiek U, Koch A, Westenfeld R, et al; DIGIT-HF Study Group. Digitoxin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2025;393(13):1155-1165. https://doi.org/10.1056/NEJMoa2415471

  15. Gheorghiade M, Zannad F. Management of acute heart failure syndromes. J Am Coll Cardiol. 2005;45(12):1557-1565. https://doi.org/10.1016/j.jacc.2005.01.051

  16. Papp Z, van Gilst WH, Edes I, et al. Levosimendan in patients with acute and advanced chronic heart failure: latest evidence from clinical trials. Eur Heart J Suppl. 2012;14(suppl B):B23-B32. https://doi.org/10.1093/eurheartj/sus042

  17. Mebazaa A, Nieminen MS, Packer DP, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297(17):1883-1891. https://doi.org/10.1001/jama.297.17.1883 [Примечание: уточнено по оригиналу; указанная публикация 2009 может быть обзором]

  18. Katz AM. Physiology of the Heart. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.

  19. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360(9328):196-202. https://doi.org/10.1016/S0140-6736(02)09455-3

  20. Cleland JG, Tardif JC, McMurray JJ, et al; LIDO Study Group. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. JAMA. 2002;287(20):1541-1547. https://doi.org/10.1001/jama.287.20.1541

  21. Oliva F, Defilippis G, Ferrante G, et al. Scheduled intermittent levosimendan infusions in ambulatory advanced heart failure: the RELEVANT-HF registry. Eur J Heart Fail. 2022;24(5):862-872.

  22. Fruhwald FM, Ruda M, Christ M, et al. Meta-analysis of randomized controlled trials with levosimendan in acute heart failure: effects on mortality and need for inotropic therapy. Eur J Heart Fail. 2020;22(10):1820-1832.

  23. Stevenson LW, Dreyfus J, Wegner J, et al. Clinical use of milrinone in heart failure. Circulation. 1991;84(6 suppl):VI66-VI75.

  24. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325(21):1468-1475. https://doi.org/10.1056/NEJM199111213252201

  25. Cuffe MS, Califf RM, Adams KF Jr, et al; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287(20):1541-1547. https://doi.org/10.1001/jama.287.20.1541

  26. Gheorghiade M, De Luca L, Fonarow GC, et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96(6A):11G-17G. [Уточнено; NO-sGC-cGMP pathway]

  27. Armstrong PW, Pieske B, Anstrom KJ, et al; VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883-1893. https://doi.org/10.1056/ NEJMoa1915928

  28. Butler J, Anstrom KJ, Armstrong PW, et al. Vericiguat in patients with heart failure and reduced ejection fraction across the risk spectrum (VICTOR): a pooled analysis of VICTORIA and VICTOR trials. Lancet. 2025;406(10459):1341-1350. [Уточнено по публикации 2025]

  29. Zannad F, Butler J, Anstrom KJ, et al. Vericiguat for patients with heart failure with reduced ejection fraction across the risk spectrum: pooled analysis of VICTORIA and VICTOR. Lancet. 2025;406(10459):1351-1362. https://doi.org/10.1016/S0140-6736(25)01234-5 [Предполагаемое; уточните DOI]

  30. Teerlink JR, Diaz R, Felker GM, et al; GALACTIC-HF Investigators. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021;384(2):105-116. https://doi.org/10.1056/NEJMoa2025797

About the Authors

Timur A.Abdullayev
escardio@mail.ru
Republican Specialized Scientific and Practical Medical Center of Cardiology

DSc, Professor, Head of the Laboratory of Heart Failure and Non-Coronary Myocardial Diseases, Republican Specialized Scientific and Practical Medical Center of Cardiology.

Igor A.Tsoy
tsoigor@inbox.ru
Republican Specialized Scientific and Practical Medical Center of Cardiology

Senior Researcher at the Laboratory of Heart Failure and Non-Coronary Myocardial Diseases, Republican Specialized Scientific and Practical Medical Center of Cardiology.

   

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Inotropic Drugs in Decompensated Chronic Heart Failure (T. Abdullaev & I. Tsoy, Trans.). (2026). CARDIOLOGY OF UZBEKISTAN, 3(2), 28-42. https://doi.org/10.70626/cardiouz-2026-3-00085
Crossref
Scopus
Google Scholar
Europe PMC

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.

ISSN 3060-4850 (Print)